Filtered By:
Specialty: Internal Medicine
Condition: Bleeding
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 325 results found since Jan 2013.
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study
CONCLUSION: In this retrospective cohort study, patients aged 65 years or older with atrial fibrillation treated with amiodarone during apixaban or rivaroxaban use had greater risk for bleeding-related hospitalizations than those treated with flecainide or sotalol.PRIMARY FUNDING SOURCE: National Heart, Lung, and Blood Institute.PMID:37216662 | DOI:10.7326/M22-3238
Source: Annals of Internal Medicine - May 22, 2023 Category: Internal Medicine Authors: Wayne A Ray Cecilia P Chung C Michael Stein Walter Smalley Eli Zimmerman William D Dupont Adriana M Hung James R Daugherty Alyson L Dickson Katherine T Murray Source Type: research
Influence of an abnormal ankle-brachial index on ischemic and bleeding events in patients undergoing percutaneous coronary intervention
CONCLUSIONS: An abnormal ABI is a risk factor for both ischemic and bleeding events after PCI. Our study findings may be helpful in determining the optimal method for secondary prevention after PCI.PMID:37077131 | DOI:10.3904/kjim.2022.348
Source: The Korean Journal of Internal Medicine - April 20, 2023 Category: Internal Medicine Authors: Hangyul Kim Seung Do Lee Hyo Jin Lee Hye Ree Kim Kyehwan Kim Jin-Sin Koh Seok-Jae Hwang Jin-Yong Hwang Jong-Hwa Ahn Yongwhi Park Young-Hoon Jeong Jeong Rang Park Min Gyu Kang Source Type: research
Effect of extended duration of thromboprophylaxis for medically ill patients
CONCLUSIONS: Extended thromboprophylaxis, especially with LMWH, showed better efficacy in venous thromboembolism reduction with increased risk of major bleeding. The beneficial effect of LMWH with extended timing has also been shown in stroke patients. Overall, extended thromboprophylaxis is associated with a positive net clinical benefit.PMID:37029050 | DOI:10.1016/j.ejim.2023.03.032
Source: European Journal of Internal Medicine - April 7, 2023 Category: Internal Medicine Authors: Xing Wang Yuqi Chen Dingke Wen Chao You Lu Ma Source Type: research
Warfarin-induced isolated spontaneous subarachnoid hemorrhage: Rare case report
CONCLUSION: Warfarin is rarely associated with isolated subarachnoid hemorrhage. This case highlights a young male patient with spontaneous SAH after warfarin therapy for acute ischemic stroke. Aneurysmal rupture and trauma should be excluded before a diagnosis of warfarin-induced SAH is made.PMID:36582886 | PMC:PMC9793204 | DOI:10.1016/j.amsu.2022.104946
Source: Annals of Medicine - December 30, 2022 Category: Internal Medicine Authors: Mohamed Sheikh Hassan Ahmet Bakir Bakar Ali Adam Nor Osman Sidow Abdiwahid Ahmed Ibrahim Ishak Ahmed Abdi Mohamud Mire Waberi Source Type: research
Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study
CONCLUSIONS: Over 12 months after initiation, apixaban and dabigatran conferred progressive increases in event free time for stroke/SE and MB vs warfarin, whereas rivaroxaban conferred an increase in stroke/SE-free time but a loss in MB-free time vs warfarin.PMID:36456387 | DOI:10.1016/j.ejim.2022.10.021
Source: European Journal of Internal Medicine - December 1, 2022 Category: Internal Medicine Authors: Steven Deitelzweig Allison Keshishian Amiee Kang Aaron Jenkins Nipun Atreja Patricia Schuler Jenny Jiang Huseyin Yuce Xiaoxi Sun Gregory Y H Lip Source Type: research
Mobile health-technology integrated care in atrial fibrillation patients with heart failure: A report from the mAFA-II randomized clinical trial
CONCLUSION: A mHealth-technology implemented ABC pathway provides consistent effects on the risks of primary outcome, rehospitalisation and bleeding, in AF patients both with and without HF. However, AF-HF patients may need tailored approaches to improve their overall prognosis, specifically to reduce the risk of recurrent AF, HF and acute coronary syndrome.PMID:36347740 | DOI:10.1016/j.ejim.2022.11.002
Source: European Journal of Internal Medicine - November 8, 2022 Category: Internal Medicine Authors: Yutao Guo Giulio Francesco Romiti Bernadette Corica Marco Proietti Niccol ò Bonini Hui Zhang Gregory Yh Lip mAF-App II trial investigators Source Type: research
